A 12-Week, Phase 2, Randomized, Double-Blind, Active-Controlled Study of LY2608204 Given as Monotherapy or in Combination With Metformin in Patients With Type 2 Diabetes Mellitus.
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 07 Dec 2012
At a glance
- Drugs LY 2608204 (Primary) ; Glimepiride
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 24 Aug 2011 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 09 Aug 2011 New trial record